VRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Valeant Pharmaceuticals International Inc's research and development for the three months ended in Mar. 2016 was $103 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2016 was $382 Mil.
This is the expense the company spent on research and development.
Valeant Pharmaceuticals International Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2016 was 81.1 (Jun. 2015 ) + 101.6 (Sep. 2015 ) + 95.9 (Dec. 2015 ) + 103.1 (Mar. 2016 ) = $382 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Valeant Pharmaceuticals International Inc Annual Data
|Research & Development||95||118||93||121||158||175||269||157||246||334|
Valeant Pharmaceuticals International Inc Quarterly Data
|Research & Development||60||61||67||59||59||56||81||102||96||103|